Antibody Drug Conjugate Therapeutics Market Size, Share and Global Trend By Mechanism of Action (HER2 Antibodies, CD30 Antibodies, Anti-CD33 Antibody, CD22 Antibody), By Disease Indication (Blood cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumor), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) and Regional Forecast, 2024-2032
KEY MARKET INSIGHTS
Antibody drug conjugate therapeutics are emerging as a potential method for the treatment of cancer. Antibody drug conjugate therapeutics are immunotherapy agents that use the potential cytotoxic molecule combined with the monoclonal antibodies through chemical linkers. This, in turn increases the ability of the drug to target the specific tumor cells. It is due to this advantage that antibody drug conjugate therapeutics have now become a hot area of research and investments.
Apart from commercially available products, there are many pipeline products that are being developed by prominent key players. For example, Asana BioSciences LLC. is developing ASN004, an antibody drug conjugate having the ability to selectively target 5T4 oncofetal antigen, which is expressed in malignant tumors. Also, many other pipeline products and strategic collaborations in this field will help the antibody drug conjugate therapeutics market to flourish at a global level.
To gain extensive insights into the market, Request for Customization
The strive to develop novel treatment and drugs for chronic disease such as cancer through increased R&D investment is a major factor driving the growth in global antibody drug conjugate therapeutics market. Also, the potential pipeline products and favorable health reimbursement are the factors that are estimated to fuel the global antibody drug conjugate therapeutics market during the forecast years.
However, the high production cost associated with antibody drug conjugate and side effect from the drugs is the major factor that can hamper the growth in global antibody drug conjugate therapeutics market.
Key Players Covered
Some of the key players present in the global antibody drug conjugate therapeutics market are Pfizer Inc., Genentech, Seattle Genetics Inc., Synthon Holding B.V., ImmunoGen Inc., AbbVie Inc., Genentech, Inc., Bayer AG, F. Hoffmann-La Roche Ltd, and other players.
SEGMENTATION
SEGMENTATION | DETAILS |
By Mechanism of Action | · HER2 Antibodies · CD30 Antibodies · Anti-CD33 Antibody · CD22 Antibody |
By Disease Indication | · Blood cancer · Breast Cancer · Ovarian Cancer · Lung Cancer · Brain Tumor · Others |
By Distribution Channel | · Hospital Pharmacy · Retail Pharmacy · Online Pharmacy |
By Geography | · North America (USA and Canada) · Europe (UK, Germany, France, Italy, Spain, Scandinavia, and Rest of Europe) · Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific) · Latin America (Brazil, Mexico and Rest of Latin America) · Middle East & Africa (South Africa, GCC and Rest of the Middle East & Africa) |
Among the segmentation of the global antibody drug conjugate therapeutics market, breast cancer accounted for the largest revenue owing to the prevalence of breast cancer cases, thus boosting the R&D in the development of drugs in the treatment of breast cancer.
Key Insights
- Mechanism of action for key products
- Patent analysis
- Pipeline analysis
- Advancement in antibody drug conjugate
- Key mergers and acquisitions
Regional Analysis
Geographically the global antibody drug conjugate therapeutics market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The antibody drug conjugate therapeutics market is anticipated to expand in North America during the forecast years owing to the favorable health reimbursement and increasing funding for research in antibody drug conjugate therapeutics. In Europe and Asia Pacific, the antibody drug conjugate therapeutics market is projected to expand by the end of 2025 owing to new product launch and increasing trend of strategic collaborations.
Key Industry Developments
- In March 2019, AstraZeneca entered into collaboration agreement with Daiichi Sankyo Company, Limited, for trastuzumab deruxtecan (DS-8201), an antibody-drug conjugate (ADC) and potential new targeted medicine for cancer treatment.
- In December 2018, Seattle Genetics Inc. received FDA approval for Adcetris for the treatment of lymphoma.
- Ongoing
- 2023
- 2019-2022
Personalize this Research
- Granular Research on Specified Regions or Segments
- Companies Profiled based on User Requirement
- Broader Insights Pertaining to a Specific Segment or Region
- Breaking Down Competitive Landscape as per Your Requirement
- Other Specific Requirement on Customization
Healthcare Clients
